Skip to content

News

Arecor commences US Phase 1 clinical trial of ultra-rapid insulin in combination with an insulin pump

Arecor’s AT247 has the opportunity to revolutionise diabetic management through creating in effect an artificial pancreas through a closed loop system Over 500 million people suffer with diabetes worldwide and AT247 has the potential to make both management easier and improve average blood glucose levels Arecor Therapeutics plc, the biopharmaceutical group advancing today’s therapies to …

Oxford BioTherapeutics and Boehringer Ingelheim Partnership Advances Second Oncology Drug Candidate into the Clinic

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, today announced that it has received another milestone payment from Boehringer Ingelheim (BI) for the progress of a second oncology drug candidate (BI 765049), discovered during the first phase of the partnership, into the clinic. In addition to OBT’s …

Arecor announces positive results from Phase 1 Trial of insulin product for diabetes patients

Arecor announces positive headline results from first phase 1 clinical trial of AT278 ultra-rapid acting insulin candidate for diabetes. AT278 delivers significantly accelerated PK/PD profile compared to Novorapid Potential to be first concentrated (500U/mL) ultra-rapid acting insulin product enabling miniaturisation of next generation insulin delivery devices. Potential to enable more effective disease management for insulin …

Surrey trust pilots the NHS’ first-of-its-kind demand-led rostering solution with Rotageek

Surrey-based Ashford and St Peter’s Hospitals NHS Foundation Trust, one of the UK’s foremost Trusts, is piloting a demand-led rostering solution with Rotageek and Locum’s Nest, who create software connecting healthcare professionals to flexible work. Together they will test the NHS’ first-of-its-kind demand-led rostering. The solution links scheduling and locums in an integrated network that …